玻璃体内注射康柏西普治疗Irvine—Gass综合征

Intravitreal injection of conbercept for the treatmaent of Irvine-Gass syndrome

目的探讨玻璃体内注射康柏西普（conbercept）治疗白内障术后囊样黄斑水肿（Irvine—Gass综合征）的效果。方法对10例（10眼）Irvine-Gass综合征进行康柏西普玻璃体内注射。观察注射后2周、1个月及3个月的视力、眼压、黄斑中心区视网膜厚度（CMRT）及眼部和全身并发症。结果所有患者注射后2周、1个月、3个月时视力及CMRT均较注射前明显改善，差异有统计学意义（P〈0．01）。注射后与注射前眼压差异无统计学意义（P〉0．05）。未发现全身和眼部并发症。结论玻璃体内注射康柏西普治疗Irvine—Gass综合征安全有效。

Objective To investigate the efficacy of intravitreal injection of conbercept for the treatment of Irvine-Gass syndrome （ IGS ）. Methods The data of 10 eyes of 10 cases with IGS were collected and they received intravitreal injection of conbercept. The best-corrected visual acuity （BCVA） , intraocular pressure （IOP）, central macular retinal thickness （CMRT） and systemic side effects were observed at 2 weeks, 1 and 3 months after injection. Results The BCVA and CMRT at 2 weeks, 1 and 3 months after injection were improved significantly. The difference was statistically significant （ P 〈 0.05 ）. The difference of IOP between before and after injection was not significant （ P 〉 0.05 ）. No ocular or systemic complication occurred. Conclusion Intravitreal injection of conbercept is effective and safe for IGS.